---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-151999"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:35:52.080939+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Allogene's cema-cel shows 41.6% MRD clearance advantage in ALPHA3 Phase 2 interim

## Summary
- 58.3% (7/12) of cema-cel patients achieved MRD negativity vs 16.7% (2/12) in observation arm.
- No CRS, ICANS, or GvHD reported; 10 of 12 cema-cel patients managed fully outpatient.
- Plasma ctDNA decreased 97.7% median in cema-cel arm vs 26.6% increase in observation at Day 45.
- Cema-cel arm had more aggressive disease (100% stage III-IV, 41.7% IPI 4-5) than observation.
- ALPHA3 targets ~220 patients; enrollment complete by end 2027; interim EFS mid-2027, primary mid-2028.

## SEC filing metadata
- accession: 0001193125-26-151999
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000119312526151999/0001193125-26-151999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000119312526151999/d49895d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-151999
- JSON: https://secwatch.observer/filing/0001193125-26-151999.json
- Plain text: https://secwatch.observer/filing/0001193125-26-151999.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.